🧠
Headache — New or Changing Presentation Structured 9-step pathway for UK GP trainees and early-career GPs · SCA exam ready
Progress 0 / 9
The full reasoning pathway — screen the secondary red-flag headache (SAH, meningitis, GCA, raised ICP/tumour), then diagnose the primary type by pattern, treat acutely and preventively, address medication overuse and safety-net.StartDecisionInvestigateActionReferStop / Admit
PresentationHeadache
Onset & time-to-peak, pattern, triggers, associated features, analgesic frequency. Examine fundi, BP, neurology, temporal arteries. A clear primary-headache pattern with normal exam needs no imaging.
Step 1 · Safety — screen secondary red flagsAny dangerous secondary cause?
  • Thunderclap — max intensity in seconds–minutes → SAH
  • Fever + neck stiffness / non-blanching rash / photophobia → meningitis
  • Age 50+ new headache + scalp tenderness / jaw claudication / visual loss → GCA
  • Progressive, worse on waking / Valsalva / posture, vomiting, papilloedema, focal or cognitive change → raised ICP / tumour
  • Pregnant >20 wk + BP ≥140/90 → pre-eclampsia · red eye + haloes + vomiting → acute angle-closure glaucoma · trauma · immunosuppression/cancer
YES — red flag
Stop · act nowEmergency / urgent
Thunderclap → 999, CT (and LP if CT −ve). Meningitis → IM/IV benzylpenicillin + 999. GCA → high-dose prednisolone immediately + same-day rheum/ophthal + ESR/CRP. Glaucoma → same-day eye unit.
NO — primary
Step 2 · ClassifyDiagnose by pattern
No bloods/imaging if classic primary pattern + normal exam. Keep a headache diary; review analgesic days/month for overuse.
Step 3 · which primary headache?
Tension-type
Bilateral, band-like
Pressing/tightening, mild–moderate, no nausea, not aggravated by activity. The commonest.
Migraine
Pulsating, 4–72 h ± aura
Photo/phonophobia, nausea, worse with activity; aura evolves over 5–60 min. Sudden focal deficit = treat as stroke/TIA, not aura.
Cluster / MOH
Autonomic · overuse
Cluster: severe unilateral orbital, restless, lacrimation/ptosis, in bouts. Medication-overuse: simple analgesia ≥15 d/mo or triptan/opioid ≥10 d/mo.
Step 7 · treat by type
Step 7 · Action — type-specific treatmentAcute + preventive
  • Migraine acute: aspirin 900 mg or ibuprofen + an antiemetic (metoclopramide 10 mg); step up to a triptan (sumatriptan 50–100 mg PO / 6 mg SC), ideally triptan + NSAID. Prevent if frequent/disabling: propranolol, amitriptyline, or topiramate (avoid in pregnancy/childbearing) ± candesartan.
  • Tension-type: aspirin/ibuprofen for episodes; amitriptyline 10–75 mg nocte for chronic prevention.
  • Cluster: sumatriptan 6 mg SC + high-flow O₂ 12–15 L/min; verapamil (specialist, ECG monitored) for prevention.
  • Medication-overuse: withdraw the overused drug (abrupt for simple analgesics/triptans), warn of transient worsening, review at 4–8 wks.
Step 6 · escalation thresholds
Step 6 · ReferEscalation thresholds
  • 999 thunderclap, meningism, GCS <15, focal neurology + headache, papilloedema with acute onset.
  • Same-day suspected GCA (after starting steroid), acute glaucoma, immunocompromised new headache, pre-eclampsia.
  • 2WW · NICE NG12 new progressive headache with personality/cognitive change, new headache in a known-cancer patient, or headache + focal neurology → urgent direct-access MRI brain (suspected CNS tumour).
  • Neurology refractory migraine on ≥2–3 preventives, suspected cluster, new daily persistent headache. Ophthalmology papilloedema, diplopia/III-nerve palsy.
Step 8 · modify triggers
Step 8 · Lifestyle — trigger managementReduce frequency
Headache diary to identify triggers · regular sleep, meals and hydration · limit caffeine and acute analgesics (MOH risk) · stress reduction/CBT, relaxation · regular aerobic exercise · address screen posture for tension-type. Riboflavin 400 mg may reduce migraine frequency.
Step 9 · safety-net
Step 9 · Safety-net & follow-upWhen to come back
Call 999 if the worst-ever sudden headache, fever + neck stiffness + rash, weakness/speech/vision change, drowsiness or seizure. Same-day if new visual loss or jaw claudication (GCA), or headache changes character. Review: diary + analgesic days at 4–8 wks; reassess preventive at 8–12 wks; re-examine and consider imaging if the pattern changes.
⚠️ Thunderclap = SAH until proven otherwise: a headache reaching maximum intensity within seconds to minutes needs emergency CT (and LP if CT negative) — never reassurance. And start steroids for suspected GCA before the ESR comes back.
1
Safety

Exclude life-threatening causes first

Ask screening questions before anything else. A single missed subarachnoid haemorrhage is career-ending. Screen every new headache patient.

Thunderclap onset "Worst headache of my life", maximal at <60 seconds → 999 Subarachnoid haemorrhage until proven otherwise; do not LP in primary care
Focal neurology New limb weakness, facial droop, dysphasia, diplopia, ataxia → 999 Stroke / cerebral venous sinus thrombosis / posterior fossa lesion
Meningism Neck stiffness, photophobia, non-blanching rash, Kernig's sign, fever → 999 Bacterial meningitis / meningoencephalitis
Papilloedema / raised ICP Postural worsening, worse lying flat/morning, vomiting, visual obscurations → Same day Brain tumour / idiopathic intracranial hypertension; arrange urgent CT
Head trauma Anticoagulated, skull fracture signs (Battle's sign, panda eyes, CSF rhinorrhoea), GCS <15 → 999 Subdural / extradural haematoma; NICE head injury guideline
Temporal arteritis Age >50, jaw claudication, scalp tenderness, visual loss, ESR >50 → Same day Giant cell arteritis; start prednisolone 40–60 mg before biopsy, urgent ophthalmology if visual symptoms
New headache in pregnancy / postpartum Especially >20 weeks with BP ≥140/90, visual symptoms, headache → 999 Pre-eclampsia / HELLP / cerebral venous thrombosis
Immunocompromised / HIV Subacute onset, weight loss, night sweats → Same day Cryptococcal meningitis / cerebral toxoplasmosis / CNS lymphoma; arrange same-day CT/LP
New headache in cancer patient Known malignancy, progressive headache, personality change → 2WW / same-day if rapidly progressive — brain metastases; urgent MRI
Acute angle-closure glaucoma Periorbital pain, eye redness, haloes, nausea, vomiting → 999 Irreversible visual loss within hours without treatment

Subarachnoid haemorrhage carries 50% mortality and up to 46% are initially misdiagnosed in primary care — most often as migraine or tension headache. The sentinel headache ("warning leak") precedes catastrophic bleed in ~20% of cases. A thunderclap headache mandates 999 regardless of subsequent resolution.

GCA causes permanent unilateral blindness in up to 25% if untreated. Treatment must not wait for biopsy results. ESR alone is insufficient — 5% of GCA have a normal ESR; CRP is more sensitive.

NICE NG12 mandates 2WW brain tumour referral for new-onset seizure with headache, or progressive neurological deficit. Raised ICP features indicate same-day rather than 2WW.

2
Diagnose

Characterise the headache — SOCRATES + triggers

Systematic history is your most powerful diagnostic tool. Most primary headaches are diagnosed on history alone.

Site
Unilateral (migraine, cluster) vs bilateral (tension-type, medication overuse). Occiput (cervicogenic, SAH). Periorbital (cluster, GCA, glaucoma).
Onset
Thunderclap (<60 sec) → SAH. Gradual over weeks → raised ICP, medication overuse, depression. Recurrent episodic → migraine, tension-type.
Character
Throbbing / pulsating → migraine. Band-like pressure → tension-type. Severe stabbing / ice-pick → trigeminal autonomic cephalalgias or primary stabbing headache.
Radiation
Neck (meningism, cervicogenic). Jaw / temple (GCA). Behind eye (cluster, glaucoma).
Associated symptoms
Nausea/vomiting, photophobia, phonophobia → migraine. Lacrimation, rhinorrhoea, eyelid ptosis / miosis → cluster. Aura (visual, sensory, speech) → migraine with aura.
Time course
Duration: 4–72 h = migraine; 15 min–3 h = cluster; 30 min–7 days = tension-type. Frequency: >15 days/month → chronic daily headache / medication overuse.
Exacerbating
Movement, coughing, sneezing (raised ICP). Menstruation, OCP, alcohol, sleep disruption (migraine). Stress (tension-type). Alcohol triggers cluster within 1 hour.
Relieving
Triptan response supports migraine diagnosis (but not diagnostic alone). Darkness/sleep for migraine. Cluster: agitation — patients pace, do not lie still (distinguishes from migraine).
Severity (0–10)
Rate at peak. ≥8/10 with rapid onset demands urgent exclusion of SAH even if previous similar attacks documented.
Diary request
Ask patient to complete headache diary for 4–8 weeks: date, duration, severity, triggers, medications used. Essential for diagnosis and overuse assessment. Migraine Trust diary app available free.

Headache diaries improve diagnostic accuracy significantly and reveal medication overuse patterns invisible in consultation. Patients frequently underestimate both frequency and analgesic use. NICE NG150 recommends offering a headache diary at first presentation.

Cluster headache is the most severely painful condition known to medicine (rated >10/10 by most patients) and is frequently misdiagnosed for years as migraine or sinusitis. The restless, agitated patient who cannot lie down is pathognomonic.

3
Diagnose

Classify the headache type using ICHD-3 criteria

Apply ICHD-3 (International Classification of Headache Disorders) criteria. Classification drives treatment — analgesic choice differs entirely between migraine and tension-type.

Migraine without aura
≥5 attacks lasting 4–72 h + ≥2 of: unilateral, pulsating, moderate/severe, worse with activity + ≥1 of: nausea/vomiting OR photophobia AND phonophobia. ICHD-3: 1.1
Migraine with aura
≥2 attacks; ≥1 fully reversible aura (visual, sensory, speech/language, motor, brainstem, retinal) lasting 5–60 min, followed or accompanied by headache within 60 min. ICHD-3: 1.2
Tension-type headache
Bilateral, pressing/tightening, mild–moderate, no nausea, no vomiting. Episodic: <15 days/month. Chronic: ≥15 days/month for >3 months. ICHD-3: 2
Cluster headache
Severe unilateral orbital/supraorbital pain lasting 15–180 min, ≥1 ipsilateral autonomic feature (lacrimation, conjunctival injection, ptosis, rhinorrhoea, miosis), agitation, ≥1 attack/48 h in cluster period. ICHD-3: 3.1
Medication overuse headache
Headache ≥15 days/month + overuse of acute medication ≥10–15 days/month for >3 months. MOST COMMON cause of chronic daily headache in UK primary care. Screen all frequent headache patients. Very common
Cervicogenic headache
Unilateral, from neck, reduced neck range of movement, precipitated by neck movement/posture, responds to cervical blockade or physiotherapy. Often coexists with migraine.
New daily persistent headache
Daily from exact onset date, lasting >3 months. Must exclude secondary causes — needs MRI. Can be post-viral (including post-COVID). Refer neurology if no explanation.
Idiopathic intracranial hypertension
Obese woman of childbearing age + daily headache + visual obscurations + pulsatile tinnitus + bilateral papilloedema. CSF pressure >25 cmH₂O on LP. 2WW referral

Medication overuse headache (MOH) affects ~1% of the UK population and is caused by overuse of triptans (>10 days/month), opioids (>10 days/month), or simple analgesics (>15 days/month). It transforms episodic migraine into chronic daily headache. The treatment is withdrawal — not escalating preventives while overuse continues. Preventives are ineffective while overuse persists.

IIH is increasing in prevalence with rising obesity rates. It causes permanent visual field loss if missed. All obese young women with daily headache deserve fundoscopy to check for papilloedema.

4
Diagnose

Targeted examination

Examination rarely changes diagnosis in primary headaches, but is essential to exclude secondary causes and reassure patients. Document findings clearly.

Blood pressure (both arms)
Hypertensive crisis (systolic >180) can cause headache. Malignant hypertension with papilloedema → same-day referral. Significant difference (>15 mmHg) between arms → consider aortic dissection.
Fundoscopy
Papilloedema = raised ICP until proven otherwise → same-day referral. Essential in all new headache presentations. Record: disc margins sharp/blurred, venous pulsation present/absent.
Temporal arteries
Palpate for tenderness, thickening, nodularity, absent pulsation in all patients >50 with new headache. GCA diagnosis requires assessment even if ESR is normal.
Full neurological exam
Cranial nerves, upper and lower limb power/reflexes/coordination, gait. Any focal deficit → same-day referral. Document clearly. Normal exam is reassuring but never excludes pathology.
Neck examination
Range of movement, Spurling's test (cervicogenic), meningism (Kernig's, Brudzinski's, nuchal rigidity). Neck stiffness + fever → 999.
Eyes
Visual acuity (Snellen), visual fields by confrontation, pupil reactions. Fixed mid-dilated pupil + severe pain → acute angle-closure glaucoma → 999. Horner's syndrome (miosis, ptosis, anhidrosis) with cluster headache.
BMI
Obesity (BMI >30) in young woman → screen for IIH. BMI is a modifiable risk factor for migraine frequency.
Pericranial muscles
Palpate temporalis, masseter, sternocleidomastoid. Tenderness present in tension-type headache. TMJ dysfunction may contribute.

Fundoscopy is the single most important examination in new headache presentations. Many GPs are deskilled — arrange ophthalmology referral if unsure of findings. Absence of venous pulsation is an early sign of raised ICP.

Normal neurological examination does not exclude a brain tumour — 40% of brain tumours present without focal signs. The combination of progressive headache + personality change + cognitive decline requires imaging even with a normal examination.

5
Diagnose

Investigations — when to test and what to request

Most primary headaches require NO investigations. Over-investigation causes anxiety without benefit. Investigate only when the history or examination suggests a secondary cause.

ESR + CRP Blood
Request if ≥50 years with new headache, jaw claudication, scalp tenderness. ESR >50 strongly supports GCA. CRP >2.45 mg/dl has higher sensitivity. Do not delay prednisolone for results if GCA is suspected clinically.
FBC, U&E, TFTs Blood
Anaemia causes headache. Hyponatraemia causes headache. Hypothyroidism causes headache. Request if no clear primary diagnosis, or if patient fails to respond to treatment.
Glucose Blood
Hypoglycaemia causes headache. Check in diabetic patients or those with episodic headache around mealtimes.
CT head Imaging
DO NOT request routinely for migraine / tension-type headache — does not reduce patient anxiety (evidence shows this). Request for: suspected SAH (sensitivity 98% at 6h), focal neurology, suspected raised ICP, first seizure, new headache in immunocompromised. Avoid routine CT
MRI brain Imaging
Superior to CT for posterior fossa, pituitary, white matter lesions. Request (via neurology referral if appropriate) for: new daily persistent headache with no cause, suspected IIH (with MRV for CVST), aura without headache, atypical migraine features.
LP (in hospital) Procedure
If CT negative and SAH still suspected — xanthochromia detectable 2–12 hours post-bleed for up to 2 weeks. Arrange same-day hospital attendance; do not perform in primary care. Opening pressure diagnostic for IIH (>25 cmH₂O).
DO NOT investigate
Typical migraine with normal examination. Typical tension-type headache. Reassurance is more effective than imaging in primary headaches (meta-analysis data).

CT sensitivity for SAH drops from 98% at 6 hours to 85% at 24 hours and 50% at 1 week. A negative CT does not exclude SAH if >6 hours post-ictus — LP is mandatory in this scenario. CTP Ottawa SAH rules can guide decision-making.

Routine neuroimaging for migraine is specifically not recommended by NICE NG150. Studies show it increases false-positive incidental findings, patient anxiety, and NHS costs without improving outcomes. Reserve CT/MRI for atypical features only.

6
Refer

Referral criteria — who, when, how urgently

Know your local neurology and ophthalmology pathways. Many areas now have rapid access headache clinics — check your CCB/ICB formulary.

999 Emergency
Thunderclap headache, focal neurology + headache, meningism, papilloedema + acute-onset, GCS <15, non-blanching rash + headache + fever, acute visual loss + headache.
Same day Urgent
Suspected GCA (start prednisolone immediately, refer same-day to rheumatology/ophthalmology). New headache in immunocompromised. Suspected cerebral venous thrombosis (headache + focal signs + pregnancy/OCP). Headache with new papilloedema on any same-day fundoscopy.
2WW 2-Week Wait
NICE NG12: New progressive headache with personality/cognitive change. New headache in patient with known cancer. Headache with new onset seizure. Headache with unexplained visual deterioration.
Routine Neurology
Refractory migraine not controlled with ≥2 preventives. Suspected cluster headache (confirm diagnosis, initiate verapamil). New daily persistent headache. Hemiplegic migraine. Migraine with brainstem aura. Suspected IIH. Atypical aura. Medication overuse headache not responding to withdrawal strategy.
Ophthalmology (urgent)
GCA with visual symptoms. Acute angle-closure glaucoma. Papilloedema on fundoscopy. Diplopia with headache (especially III nerve palsy → posterior communicating artery aneurysm until proven otherwise).
Rheumatology (urgent)
GCA: refer same day alongside prednisolone commencement. Temporal artery biopsy within 2 weeks of starting steroids. Check local pathway — some areas manage GCA in primary care under specialist guidance.
Primary care management
Episodic migraine responding to acute treatment. Episodic tension-type headache. Medication overuse headache (withdrawal + support). Cervicogenic headache (physiotherapy). Headache associated with stress/anxiety/depression (psychological interventions).

Cluster headache is best initiated under neurological supervision. Verapamil (first-line prophylaxis, up to 480 mg/day) requires ECG monitoring before and after dose escalation due to risk of heart block. Subcutaneous sumatriptan and high-flow oxygen are the only evidence-based acute treatments.

III nerve palsy + headache mandates same-day neurosurgical assessment — a posterior communicating artery aneurysm compresses the oculomotor nerve from outside, producing a painful, pupil-involving third nerve palsy. This is a neurosurgical emergency with catastrophic rupture risk.

NICE NG12 mandates 2WW referral for progressive neurological deficit including headache. The RCP recommends urgent-access headache clinics (seen within 2 weeks) rather than A&E for urgent but non-emergency cases.

7
Treat

Drug ladder — acute and preventive treatment

Treat the right condition. Ensure medication overuse is excluded before starting preventives. Counsel patients that preventives take 8–12 weeks to achieve full effect.

Migraine — Acute Treatment

Mild–moderate attacks
Aspirin + Metoclopramide 1st line
Aspirin 900 mg PO at onset + Metoclopramide 10 mg. Metoclopramide improves gastric absorption and treats nausea. Ibuprofen 400–600 mg is an alternative NSAID.
Moderate–severe attacks / NSAID failure
Triptan 1st line
Sumatriptan 50–100 mg PO (or 6 mg SC for fastest onset, or 20 mg nasal spray). Zolmitriptan 2.5 mg PO / nasal if sumatriptan fails. Avoid in cardiovascular disease, uncontrolled hypertension, haemiplegic migraine.
Triptan + NSAID combination
Sumatriptan + Naproxen Superior
Sumatriptan 85 mg + Naproxen 500 mg (Treximet — not always available; prescribe separately). Evidence shows 20% better pain-free response than either alone. Reduces recurrence.
Menstrual migraine (perimenstrual only)
Frovatriptan / Naratriptan Mini-prophylaxis
Frovatriptan 2.5 mg BD or Naratriptan 1 mg BD starting 2 days before expected onset for 6 days. Longer half-life than sumatriptan. Reduces menstrual attacks by 50%.

Migraine — Preventive Treatment (≥4 attacks/month or disabling)

Step 1Propranolol 40–120 mg BD (or metoprolol 50–200 mg/day). First-line. Reduces attacks by 50% in 50% of patients. Avoid in asthma, depression, athletes. Start low, titrate over 4 weeks.
Step 1Amitriptyline 10–75 mg nocte (especially if coexistent depression, insomnia, or tension-type overlap). Start at 10 mg; increase by 10 mg weekly. Warn about morning sedation, dry mouth, constipation.
Step 1Topiramate 25–100 mg BD. NICE-recommended. Effective but side-effects common (cognitive slowing "dopamax", paraesthesia, weight loss). Contraindicated in pregnancy — teratogenic. Use effective contraception. Start at 25 mg nocte.
Step 2Candesartan 8–16 mg OD. Off-label but RCT evidence. Good tolerability. Useful in patients unable to take beta-blockers or amitriptyline. Monitor renal function and BP.
Step 3CGRP monoclonal antibodies — Erenumab 70–140 mg SC monthly, Fremanezumab, Galcanezumab, Eptinezumab. Specialist initiation only via neurology, for patients failing ≥3 preventives. Highly effective (40–70% reduction). NHS criteria: ≥4 migraine days/month + 3 failed preventives.
Step 4OnabotulinumtoxinA (Botox) 155 units across 31 injection sites every 12 weeks. Specialist only. Licensed for chronic migraine (>15 days/month, >8 migraine days). PREEMPT protocol. Reduces headache days by ~9/month.

Tension-Type Headache — Acute

Episodic
Aspirin / Ibuprofen / Paracetamol 1st line
Ibuprofen 400 mg PO or Aspirin 500–1000 mg. Paracetamol 1 g less effective for tension-type than NSAIDs. Avoid opioids — increase MOH risk. Limit acute analgesic use to <15 days/month.
Chronic tension-type (preventive)
Amitriptyline 1st line
Amitriptyline 10–75 mg nocte. Only evidence-based pharmacological preventive for chronic tension-type. Mirtazapine 30 mg nocte if amitriptyline not tolerated. Venlafaxine 75–150 mg if depression coexists.

Cluster Headache — Acute (refer for confirmation)

Attack abort
Sumatriptan SC + O₂ Only evidence-based
Sumatriptan 6 mg SC (fastest; injectable preferred over oral). High-flow O₂ 100% at 12–15 L/min via non-rebreather mask for 15–20 min (prescribe on FP10). Both can be used in same attack.
Preventive (transitional)
Verapamil + short oral prednisolone Under specialist
Verapamil 80 mg TDS initially, up to 480 mg/day (specialist-initiated). ECG before and after dose change (AV block risk). Prednisolone 60 mg reducing course to bridge while verapamil takes effect.

Medication Overuse Headache — Withdrawal

Step 1Explain and agree withdrawal plan. Abrupt withdrawal preferred for opioids and triptans. Gradual reduction for high-dose analgesics. Expect 2–4 weeks of worsening before improvement. Give written information.
Step 2Withdrawal headache management: NSAID bridge (naproxen 500 mg BD for 2 weeks), or prednisolone 60 mg → taper over 6 days. Antiemetics as needed (prochlorperazine 3 mg buccal).
Step 3Start preventive treatment after withdrawal (preventives ineffective during overuse). Amitriptyline 10–75 mg nocte or topiramate 25–100 mg BD based on headache type.
Step 4Specialist referral if withdrawal fails, if opioid dependence is suspected, or if coexistent psychiatric disorder complicates management.

Triptans are 5-HT1B/1D agonists causing vasoconstriction and blocking CGRP release. They are most effective when taken at headache onset before central sensitisation develops (do not wait for severe pain). The 24-hour rule: most triptans should not be repeated within 24 hours. Maximum 10 days/month to avoid MOH.

CGRP monoclonal antibodies represent a paradigm shift in migraine prevention — the first treatments specifically designed for migraine (not repurposed from other conditions). NHS England criteria require 4+ migraine days/month and failure of 3 prophylactics. Erenumab (Aimovig) 70 mg SC monthly is the most widely used.

Topiramate teratogenicity: Associated with oral clefts and reduced birth weight. MHRA issued a safety warning in 2023. Must not be used without effective contraception. Discuss with woman before prescribing.

8
Lifestyle

Non-pharmacological interventions — lifestyle is treatment

Lifestyle interventions reduce migraine frequency comparably to first-line preventive drugs in trials. Address these at every appointment — not as afterthought but as core treatment.

Sleep regularity Target 7–9 hours at consistent times. Both too little AND too much sleep trigger migraine. "Weekend migraines" are a classic sleep-excess trigger — advise maintaining weekday routine on weekends.
Hydration 1.5–2 L water/day minimum. Dehydration is a common and modifiable trigger. Advise patients to front-load fluid intake in the morning. Coffee is a double-edged trigger — regular intake prevents withdrawal headache but excess worsens.
Regular meals, no skipping Blood glucose fluctuations trigger migraine. Three meals per day at consistent times. Advise carrying snacks. Identify any dietary triggers using headache diary (common: aged cheese, red wine, processed meat, MSG).
Caffeine management Regular moderate intake acceptable (<200 mg/day = 2 cups coffee). Caffeine excess AND sudden withdrawal both trigger headache. Advise gradual reduction if overusing. Caffeine-containing analgesics (Syndol, Solpadeine) increase MOH risk significantly.
Stress management Stress is the most commonly reported trigger. CBT reduces migraine frequency by 30–50% (comparable to drug prophylaxis). Refer via IAPT if available. Mindfulness-Based Stress Reduction (MBSR) has RCT evidence. GP wellness prescription.
Regular aerobic exercise 3 × 40 min/week aerobic exercise (walking, swimming, cycling) reduces migraine frequency comparably to topiramate in one RCT. Start low — intense exercise can trigger attacks initially. Build up gradually over 6–8 weeks.
Screen and posture hygiene Prolonged screen use, poor ergonomics, and forward head posture are key contributors to tension-type and cervicogenic headache. Advise 20-20-20 rule (every 20 min, look 20 feet away for 20 seconds). Workstation assessment referral.
Alcohol Alcohol (particularly red wine, beer) is a common trigger. Even small amounts can trigger cluster attacks within 1 hour of ingestion. Advise alcohol diary. AUDIT score — address alcohol misuse as separate problem if detected.
OCP and hormonal factors Combined OCP can worsen migraine with aura and is contraindicated (UKMEC 4) due to increased stroke risk. Switch to progestogen-only pill. Perimenopause commonly worsens migraine — discuss HRT (oestrogen stabilises menstrual migraine triggers).
Weight management Obesity (BMI >30) doubles migraine frequency and is a risk factor for IIH. 10% weight loss reduces migraine days by ~30%. Refer to structured weight management programme where available. Topiramate has weight-loss side effect that can be advantageous.

Exercise vs topiramate (Varkey et al., Cephalalgia 2011): 3 × 40-min aerobic exercise/week was as effective as topiramate 100 mg/day in reducing migraine days (both reduced by ~2 days/month). Exercise has no side effects and positive cardiovascular, metabolic, and psychological benefits.

CBT for headache has a systematic review NNT of ~2 for clinically meaningful improvement. It is superior to pharmacological treatment for chronic daily headache and MOH because it addresses the central sensitisation and catastrophising that perpetuates chronic pain.

OCP + migraine with aura: Migraine with aura is an independent risk factor for ischaemic stroke (OR 2.2). Combined OCP further increases this risk (OR 8.7 combined). UKMEC category 4 (contraindicated). Always ask about aura before prescribing hormonal contraception.

9
Safety

Follow-up, monitoring, and safety-netting

Safety-net every patient with a clear plan. Document the safety-net advice given. Follow-up intervals depend on treatment complexity and diagnosis confidence.

4–6 weeks First review
Review headache diary. Assess acute medication frequency (screen for emerging MOH: >10 days/month triptans, >15 days/month simple analgesics). Check preventive medication tolerability. Adjust dose. Reinforce lifestyle changes.
8–12 weeks Preventive review
Assess preventive efficacy (target 50% reduction in headache days). If no improvement, check adherence and correct diagnosis before escalating. Consider dose increase or switch. Review triggers from diary.
6 months Stability review
Consider stepping down preventive if headache-free for 6 months. Gradual withdrawal over 2–3 months. Review QoL impact (MIDAS or HIT-6 questionnaire). Re-evaluate OCP, hormonal factors in women.
GCA monitoring
If on prednisolone for GCA: ESR/CRP monthly, bone protection (alendronic acid + calcium/vitamin D), glucose, BP, weight, cataracts. Taper: 5 mg/month once <20 mg, 1 mg/month below 10 mg. Duration: typically 1–2 years, sometimes lifelong.
Verapamil monitoring
12-lead ECG before starting and after each dose increase (PR interval: stop if >240 ms). LFTs and FBC at 6 months. Cluster headache: continue for full cluster period + 2 weeks, then taper.
Topiramate monitoring
Contraception review at every appointment. Kidney stones (increase fluid intake). Cognitive effects — use word-finding test. Bicarbonate if metabolic acidosis suspected (anorexia, fatigue, hyperventilation).
Safety-net 999
New thunderclap headache or sudden severe onset. Any new focal neurological deficit. Neck stiffness + fever ± rash. Severe headache with visual loss. Reduced consciousness. Written safety-net — patient can show to paramedics.
Safety-net same-day
New headache in someone with cancer / HIV / immunosuppression. Headache worsening despite treatment. New scalp tenderness / jaw claudication in patient >50. Postural worsening (flat/standing) of headache. New visual symptoms with headache.
Tools for monitoring
MIDAS (Migraine Disability Assessment): validates treatment response, supports referral. HIT-6 (Headache Impact Test): scored 1–78; >56 = severe impact. PHQ-9 if depression screen positive. Headache diary ongoing throughout treatment.

Medication overuse headache develops silently — most patients are unaware they are overusing. Review headache diaries for analgesic frequency at every appointment, not just headache frequency. Once MOH is established, preventives are ineffective until overuse is stopped.

GCA relapse rate is 40–50% during prednisolone taper. Patients must know to contact GP immediately if jaw claudication or visual symptoms recur — even on treatment. Visual loss is irreversible once established.

MIDAS score is an RCGP curriculum competency — know how to use and interpret it. Score >21 = grade IV (severe disability) and supports preventive treatment and specialist referral. It is also used to demonstrate treatment response to commissioners and for CGRP criteria.

Educational use only. Pathway based on: NICE NG150 (Headaches in over 12s, 2021), NICE NG12 (Suspected cancer referral, 2023 update), ICHD-3 (International Classification of Headache Disorders 3rd edition), British Association for the Study of Headache (BASH) guidelines, NHS England CGRP prescribing guidance, MHRA topiramate safety guidance (2023), RCP guidance on GCA. Always adapt to individual patient context, local formulary, and current NICE/BNF guidance.